Access industry insights to enable ICH E6(R3) success.
For more than 20 years, Avoca, a WCG company, has surveyed the industry to gain an understanding of key trends affecting clinical development in order to provide insights that can strengthen relationships and enhance R&D quality and productivity. In 2024, our survey explored awareness of impending ICH E6(R3) guidelines and reaction to draft guidance about roles, data governance, and documentation. With the finalization of Annex 1 guidance in January, our goal for 2025 was to understand industry actions toward adoption and implementation, as well as impact on clinical trial design and execution.
Explore reactions to the finalized guidelines in terms of impact, adoption, and perceived challenges through key findings summarized in this report to gain a multi-faceted view from the perspectives of sponsors, providers, and site personnel. Additionally, see shifts in high-level metrics against 2024 results and identified information and support needs that will foster collaboration and successful implementation.
Download the The 2025 Avoca State of the Industry Report
Submit the form to access actionable insights to meet and maintain ICH E6(R3) compliance.